Drug Profile
OBI 888
Alternative Names: Globo H mAb; OBI-888Latest Information Update: 19 Jul 2022
Price :
$50
*
At a glance
- Originator OBI Pharma
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 05 Jul 2022 Discontinued - Phase-I/II for Solid tumours (Late-stage disease, Metastatic disease) in Taiwan, USA (IV)
- 16 Mar 2021 Phase I/II development in Solid tumours (Late-stage disease, Metastatic disease) is still ongoing in USA (IV) (OBI Pharma pipeline, March 2021)
- 08 Apr 2020 OBI Pharma suspends the enrolment in phase I/II trial in Solid tumours (Late-stage disease, Metastatic disease) in USA (IV) for three months